$SLRX
Salarius Pharmaceuticals, Inc.

2019 Q4 Form 10-Q Financial Statement

#000161521919000054 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $1.040M $874.9K $469.1K
YoY Change 537.77% 86.54% 13.41%
Cost Of Revenue $91.94K
YoY Change -38.2%
Gross Profit $377.1K
YoY Change 42.39%
Gross Profit Margin 80.4%
Selling, General & Admin $1.760M $3.490M $1.880M
YoY Change -3.3% 85.64% -61.87%
% of Gross Profit 498.52%
Research & Development $1.340M $1.141M $353.6K
YoY Change 613.68% 222.65% -92.54%
% of Gross Profit 93.77%
Depreciation & Amortization $10.00K $0.00 $60.00K
YoY Change -80.0% -100.0% -25.0%
% of Gross Profit 15.91%
Operating Expenses $3.100M $4.635M $782.6K
YoY Change 41.93% 492.3% -92.03%
Operating Profit -$3.760M -$313.5K
YoY Change 1099.36% -96.67%
Interest Expense $180.0K -$752.00 $6.064K
YoY Change 1700.0% -112.4% -92.42%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$1.880M -$2.630M -$2.640M
YoY Change -6.47% -0.38% -71.7%
Income Tax
% Of Pretax Income
Net Earnings -$1.880M -$2.628M -$307.5K
YoY Change -6.41% 754.68% -96.71%
Net Earnings / Revenue -180.77% -300.33% -65.55%
Basic Earnings Per Share
Diluted Earnings Per Share -$461.9K -$728.5K -$3.667M
COMMON SHARES
Basic Shares Outstanding 4.069M shares 18.07M shares 18.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.700M $4.000M $13.00M
YoY Change -62.24% -69.23% -66.58%
Cash & Equivalents $3.739M $4.000M $12.96M
Short-Term Investments $0.00
Other Short-Term Assets $136.1K $119.0K $500.0K
YoY Change 510.98% -76.21% -54.55%
Inventory $223.5K
Prepaid Expenses
Receivables $20.99K
Other Receivables $0.00
Total Short-Term Assets $4.695M $5.239M $13.68M
YoY Change -26.42% -61.71% -66.26%
LONG-TERM ASSETS
Property, Plant & Equipment $25.02K $28.14K $127.1K
YoY Change -33.34% -77.86% -68.31%
Goodwill $8.866M $8.866M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $308.7K $324.5K $100.0K
YoY Change 57.95% 224.51%
Total Long-Term Assets $9.200M $9.219M $253.7K
YoY Change 3849.07% 3533.86% -61.22%
TOTAL ASSETS
Total Short-Term Assets $4.695M $5.239M $13.68M
Total Long-Term Assets $9.200M $9.219M $253.7K
Total Assets $13.89M $14.46M $13.94M
YoY Change 110.08% 3.73% -66.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.791M $1.643M $1.279M
YoY Change 371.58% 28.44% 39.2%
Accrued Expenses $200.0K $200.0K $1.600M
YoY Change -75.0% -87.5% -58.97%
Deferred Revenue $500.0K $1.580M $0.00
YoY Change -87.52%
Short-Term Debt $500.0K $700.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.300M $4.700M $2.888M
YoY Change 198.14% 62.75% -41.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.300M $4.700M $2.888M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.314M $4.721M $2.888M
YoY Change -57.98% 63.47% -42.55%
SHAREHOLDERS EQUITY
Retained Earnings -$12.08M -$10.19M -$131.0M
YoY Change 134.94% -92.22% 27.08%
Common Stock $451.00 $3.756K $1.807K
YoY Change 122.17% 107.86% 3.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.58M $9.737M -$1.488M
YoY Change
Total Liabilities & Shareholders Equity $13.89M $14.46M $13.94M
YoY Change 110.08% 3.73% -66.18%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$1.880M -$2.628M -$307.5K
YoY Change -6.41% 754.68% -96.71%
Depreciation, Depletion And Amortization $10.00K $0.00 $60.00K
YoY Change -80.0% -100.0% -25.0%
Cash From Operating Activities -$2.640M -$5.540M -$2.790M
YoY Change -15.92% 98.57% -65.34%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.610M $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $5.610M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.380M -210.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.640M -5.540M -2.790M
Cash From Investing Activities 0.000 5.610M 0.000
Cash From Financing Activities 2.380M -210.0K 0.000
Net Change In Cash -260.0K -140.0K -2.790M
YoY Change -91.72% -94.98% -85.19%
FREE CASH FLOW
Cash From Operating Activities -$2.640M -$5.540M -$2.790M
Capital Expenditures $0.00
Free Cash Flow -$2.790M
YoY Change -65.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001615219
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2019Q2 flks Revenue From Grants Extension Term
RevenueFromGrantsExtensionTerm
P6M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36812
dei Entity Registrant Name
EntityRegistrantName
SALARIUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5087339
dei Entity Address Address Line1
EntityAddressAddressLine1
2450 Holcombe Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite J 608
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77021
dei City Area Code
CityAreaCode
346
dei Local Phone Number
LocalPhoneNumber
772-0346
dei Security12b Title
Security12bTitle
Common Stock, $ 0.0001 par value
dei Trading Symbol
TradingSymbol
SLRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4068520 shares
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3999676 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3228288 USD
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2903493 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1239708 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
249086 USD
CY2019Q3 us-gaap Assets Current
AssetsCurrent
5239384 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6380867 USD
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28144 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37525 USD
CY2019Q3 us-gaap Goodwill
Goodwill
8865909 USD
CY2018Q4 us-gaap Goodwill
Goodwill
0 USD
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
324509 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
195431 USD
CY2019Q3 us-gaap Assets
Assets
14457946 USD
CY2018Q4 us-gaap Assets
Assets
6613823 USD
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1643083 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
373834 USD
CY2019Q3 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
245603 USD
CY2018Q4 flks Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
628990 USD
CY2019Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
4429 USD
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
5946 USD
CY2019Q3 flks Accrued Series A Preferred Units Current
AccruedSeriesAPreferredUnitsCurrent
0 USD
CY2018Q4 flks Accrued Series A Preferred Units Current
AccruedSeriesAPreferredUnitsCurrent
2869412 USD
CY2019Q3 us-gaap Notes Payable Current
NotesPayableCurrent
749157 USD
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1580394 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4006755 USD
CY2019Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
498247 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2019Q3 us-gaap Liabilities
Liabilities
4720913 USD
CY2018Q4 us-gaap Liabilities
Liabilities
7884937 USD
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3768672 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2338899 shares
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3756184 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2032763 shares
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
3756 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
2033 USD
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19927156 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3867290 USD
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10193879 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5140437 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
9737033 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1271114 USD
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14457946 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6613823 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
874949 USD
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
469051 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2426362 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1312752 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1140909 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
353607 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2680982 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
803846 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3494205 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
428958 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5950431 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1093596 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
4635114 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
782565 USD
us-gaap Operating Expenses
OperatingExpenses
8631413 USD
us-gaap Operating Expenses
OperatingExpenses
1897442 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3760165 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-313514 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6205051 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-584690 USD
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
CY2018Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-752 USD
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6064 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18413 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6924 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2630069 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-307450 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5055790 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-577766 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2348 USD
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
2348 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2627721 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-307450 USD
us-gaap Net Income Loss
NetIncomeLoss
-5053442 USD
us-gaap Net Income Loss
NetIncomeLoss
-577766 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2630069 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-307450 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5055790 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-577766 USD
CY2019Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24580 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
88015 USD
CY2019Q3 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-2630069 USD
CY2018Q3 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-332030 USD
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-5055790 USD
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-665781 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.73
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.20
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.68
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.47
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
CY2018Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3605913 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1653340 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3002736 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1407062 shares
us-gaap Net Income Loss
NetIncomeLoss
-5053442 USD
us-gaap Net Income Loss
NetIncomeLoss
-577766 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
123174 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12713 USD
us-gaap Share Based Compensation
ShareBasedCompensation
579721 USD
us-gaap Share Based Compensation
ShareBasedCompensation
52781 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1130848 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-690 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1169 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
206956 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
274432 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-593351 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-452102 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-235817 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
29383 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1517 USD
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-21728 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2426361 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3687248 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
0 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-1290098 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8943538 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3789651 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
5403634 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
204274 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5607908 USD
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
0 USD
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
250000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1508179 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2050269 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
133594 USD
us-gaap Payments Of Dividends
PaymentsOfDividends
58959 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
171060 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1203525 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1741310 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2132105 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5530961 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6131781 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
519337 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3999676 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6050298 USD
us-gaap Interest Paid Net
InterestPaidNet
6867 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
us-gaap Stock Issued1
StockIssued1
110474 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2869412 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
920217 USD
flks Prepaid Expense Financed By Note Payable
PrepaidExpenseFinancedByNotePayable
0 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2900426 USD
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
0 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
33896 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-381549 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-3315871 USD
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2025269 USD
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
24768 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
29539 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
111233 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-1184140 USD
CY2018Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
28013 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
24580 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-307450 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-1488157 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1271114 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4377591 USD
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110474 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
35407 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1522076 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1730282 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-99758 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-6034 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-903645 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
732913 USD
CY2019Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
11093561 USD
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
538280 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2627721 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
9737033 USD
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, Salarius’ management evaluates its estimates, including those related to revenue recognition, fair value of tangible and intangible assets, research and development, accrued expenses, contingencies and equity-based compensation. Salarius bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results could differ from those estimates.</span></div>
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2903493 USD
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2000000.0 USD
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4100000 USD
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
110474 USD
CY2018Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2018Q4 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
210333 USD
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 numberOfReportableUnits
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
389488 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
51926 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:700;line-height:120%;">Reclassification</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial';font-size:10pt;font-weight:400;line-height:120%;">Certain reclassifications have been made to the prior-year financial statements to conform to the current-year presentation.</span></div>
CY2019Q3 flks Class Of Warrant Or Right Period Warrants Or Rights Unexercisable
ClassOfWarrantOrRightPeriodWarrantsOrRightsUnexercisable
P6M
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2426362 USD
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1312752 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7802709 USD
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-18034908 USD
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-2.08
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-4.81
CY2019Q3 flks Prepaid Clinical Trial Expense
PrepaidClinicalTrialExpense
247460 USD
CY2019Q3 us-gaap Prepaid Insurance
PrepaidInsurance
873277 USD
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
16484 USD
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
118971 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
22269 USD
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1239708 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
249086 USD
CY2011Q4 us-gaap Minority Interest Ownership Percentage By Noncontrolling Owners
MinorityInterestOwnershipPercentageByNoncontrollingOwners
0.02
CY2016Q2 flks Revenue From Grants Maximum Award
RevenueFromGrantsMaximumAward
18700000 USD
CY2016Q2 flks Revenue From Grants Award Term
RevenueFromGrantsAwardTerm
P3Y
CY2019Q3 flks Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales
RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales
0.01
CY2019Q3 flks Revenue From Grants Matching Funds Requirement
RevenueFromGrantsMatchingFundsRequirement
0.50
CY2019Q3 flks Revenue From Grants Aggregate Amount Received
RevenueFromGrantsAggregateAmountReceived
9600000 USD
CY2019Q3 flks Revenue From Grants Aggregate Amount Received Current Funding Available
RevenueFromGrantsAggregateAmountReceivedCurrentFundingAvailable
9100000 USD
flks Revenue From Grants Current Funding Received
RevenueFromGrantsCurrentFundingReceived
0 USD
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1580394 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4006755 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4377591 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10617 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2869412 USD
CY2018Q4 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
355676 shares
CY2018Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
110474 USD
CY2019Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
142711 shares
CY2019Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.17
CY2019Q3 flks Class Of Warrant Or Right Threshold Consecutive Trading Days
ClassOfWarrantOrRightThresholdConsecutiveTradingDays
10 trading_Days
CY2019Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y6M
CY2019Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y3M21D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47477 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
52781 USD
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
37419 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
101082 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.00
flks Share Based Compensation Arrangement By Share Based Payment Award Options Options From Business Acquired
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsFromBusinessAcquired
90279 shares
flks Share Based Compensation Arrangements By Share Based Payment Award Options Options From Business Acquired Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOptionsFromBusinessAcquiredWeightedAverageExercisePrice
102.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
191361 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M28D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
91059 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
101.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y5M12D
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
610114 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M19D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
101082 shares
CY2019Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
4429 USD
CY2018Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
5946 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2630069 USD
CY2018Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-307450 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5055790 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-577766 USD
CY2019Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24580 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
88015 USD
CY2019Q3 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-2630069 USD
CY2018Q3 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-332030 USD
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-5055790 USD
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-665781 USD
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3605913 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1653340 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3002736 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1407062 shares
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.73
CY2018Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.20
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.68
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
88015 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.47
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24580 USD

Files In Submission

Name View Source Status
0001615219-19-000054-index-headers.html Edgar Link pending
0001615219-19-000054-index.html Edgar Link pending
0001615219-19-000054.txt Edgar Link pending
0001615219-19-000054-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
flks-20190930.htm Edgar Link pending
flks-20190930.xsd Edgar Link pending
flks-20190930_cal.xml Edgar Link unprocessable
flks-20190930_def.xml Edgar Link unprocessable
flks-20190930_htm.xml Edgar Link completed
flks-20190930_lab.xml Edgar Link unprocessable
flks-20190930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrx20190930ex-311.htm Edgar Link pending
slrx20190930ex-312.htm Edgar Link pending
slrx20190930ex-321.htm Edgar Link pending